Biopharma Bites: Teva, Kinaset Funding Wins, Camzyos Teen Approval, Lynk and Lyra’s Mixed Fortunes

No recent news found in search results on Teva, Kinaset pulling in funds, Camzyos winning approval in teens, or contrasting fortunes for Lynk and Lyra as of early 2026.

Recent biopharma funding highlights include AirNexis Therapeutics' $200M Series A for COPD drug AN01, Medipost's $140M for cell therapies, SonoThera's $125M Series B for genetic medicines, and 32 Biosciences' $40M Series A for GI therapeutics.2

Broader 2026 biotech financing shows investor focus on late-stage clinical programs in immunology, genetic medicine, and chronic diseases ahead of J.P. Morgan conference.24

Sources:

2. https://www.pharmexec.com/view/roundup-pharma-funding-surge-ahead-jp-morgan-2026

4. https://www.biospace.com/business/early-stage-biotechs-feel-the-squeeze-as-funding-favors-derisked-assets-jpm